China Pharma 

$0.7842
53
-$0.01-0.86% 今天

統計

當日最高
0.8225
當日最低
0.7406
52週高點
2.05
52週低點
0.38
成交量
20,539
平均成交量
282,393
市值
3.94M
本益比
-
股息殖利率
-
股息
-

財報

18May預期
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
-0.2
-0.13
-0.07
0
預期EPS
0
實際EPS
-0.1988

財務

-104.57%利潤率
未盈利
2019
2020
2021
2022
2023
2024
9.06M營收
-9.47M淨利

其他人也在關注

此清單是根據在 Stock Events 上追蹤 CPHI 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

China Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical products. The company primarily caters to hospitals and independent retailers throughout mainland China. Its comprehensive product portfolio encompasses diverse formulations, including powdered and liquid injectables, oral tablets, capsules, and cephalosporin-based oral solutions. CPHI's extensive range of medical solutions targets various health conditions. For neurological and cognitive health, it offers Cerebroprotein Hydrolysate injections to address memory decline and attention deficits, and Gastrodin injections for symptoms such as fatigue, lack of concentration, sleep disturbances, and traumatic brain syndromes. Cardiovascular and cerebrovascular treatments include Propylgallate and Ozagrel Sodium for conditions like cerebral thrombosis, coronary heart disease, and post-surgical recovery, as well as Alginic Sodium Diester injections targeting ischemic heart disease, cerebrovascular ailments, and hyperlipoproteinemia. Additionally, CPHI provides Bumetanide injections for edema management and Candesartan for hypertension. The company also produces a variety of anti-infective medications. These feature Roxithromycin dispersible tablets for throat infections (pharyngitis and tonsillitis), and Cefaclor dispersible tablets effective against conditions such as otitis media, lower respiratory tract infections, urinary tract infections, and skin/soft tissue infections. Other anti-infectives include Cefalexin capsules for acute tonsillitis, Andrographolide for sore throats stemming from upper respiratory tract infections, and Clarithromycin available in both granule and capsule forms. For pain and cold relief, CPHI offers sustained-release tablets containing Naproxen Sodium and Pseudoephedrine Hydrochloride. Furthermore, CPHI manufactures treatments for digestive disorders, including Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeprazole. The product lineup extends to Vitamin B6 injections, Granisetron Hydrochloride injections for alleviating nausea and vomiting induced by cancer therapies (radiotherapy and chemotherapy), and dietary supplements like Noni Enzyme. Complementing its medical offerings, the company also provides health-related products such as sanitizers and protective masks. The company distributes its offerings via a network of third-party distributors, augmented by its own 16 sales offices and a team of around 1,000 sales professionals. Established in 1993, China Pharma Holdings, Inc. maintains its headquarters in Haikou, located in the People's Republic of China.
Show more...
執行長
Ms. Zhilin Li
員工
224
國家
美國
ISIN
US16941T4013

上市

0 Comments

分享你的想法

FAQ

China Pharma 今天的股價是多少?
CPHI 目前價格為 $0.78 USD,過去 24 小時下跌了 -0.86%。在圖表上更密切關注 China Pharma 股票的表現。
China Pharma 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,China Pharma 的股票以代號 CPHI 進行交易。
China Pharma 的股價在上漲嗎?
CPHI 股票較上週上漲 +9.62%,本月下跌 -24.6%,過去一年 China Pharma 下跌 -57.52%。
China Pharma 的市值是多少?
今天 China Pharma 的市值為 3.94M
China Pharma 上一季度的財報如何?
CPHI 上一季度的財報為每股 -0.2 USD,預估為 0 USD,帶來 -∞% 的驚喜。下一季度的預估財報為每股 不適用 USD。
China Pharma 去年的營收是多少?
China Pharma 去年的營收為 9.06MUSD。
China Pharma 去年的淨利是多少?
CPHI 去年的淨收益為 -9.47MUSD。
China Pharma 有多少名員工?
截至 June 16, 2026,公司共有 224 名員工。
China Pharma 位於哪個產業?
China Pharma從事於Health & Wellness產業。
China Pharma 何時完成拆股?
China Pharma 上次拆股發生於 April 15, 2025,比例為 1:10。
China Pharma 的總部在哪裡?
China Pharma 的總部位於 美國 的 Haikou。